The role of epidermal growth factor receptor in advanced non-small cell lung carcinoma

Annals of Medicine

Volumn 35, Issue 7, 2003, Pages 450-457

  Jänne, Pasi A ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Chemotherapy; Epidermal growth factor receptor; Lung carcinoma; Non small cell; Receptor tyrosine kinase

Indexed keywords

ANTINEOPLASTIC AGENT; CANERTINIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IFOSFAMIDE; LAPATINIB; NAVELBINE; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR;

ACNE; ADVANCED CANCER; ALLERGY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CHILL; CLINICAL TRIAL; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFECT; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FEVER; HEADACHE; HUMAN; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; META ANALYSIS; NAUSEA; PRIORITY JOURNAL; PROTEIN FUNCTION; QUALITY OF LIFE; RASH; REVIEW; STOMATITIS; TOXICITY; TRADITIONAL MEDICINE; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; FORECASTING; HUMANS; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0242660423     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/07853890310010889     Document Type: Review

References (46)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
3. Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999;17:3188-94.
4. Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, et al. Gemcitabine plus best supportive care (BSC) versus BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000;83:447-53.
5. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
6. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92-8.
7. Kelly K, Crowley J, Bunn PA, Jr, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-8.
8. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH, Gandara DR, et al. Twenty-Two Years of Phase III Trials for Patients With Advanced Non-Small-Cell Lung Cancer: Sobering Results. J Clin Oncol 2001;19:1734-42.
9. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M, et al. Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 2001; 357:1478-84.
10. Greco FA, Gray JR, Jr, Thompson DS, Burris HA 3rd, Erland JB, Barton JH, Jr, et al. Prospective randomized study of four novel chemotherapy regimens in patients with advanced non-small cell lung carcinoma: a minnie pearl cancer research network trial. Cancer 2002;95:1279-85.
11. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase 111 trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18-2354-62.
12. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
13. Massarelli E, Andre F, Liu DD, Lee JJ, Wolf M, Fandi A, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003;39:55-61.
14. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
15. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-50.
16. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-65.
17. Fontanini G, De Laurentiis M, Vignati S, Chine S, Lucchi M, Silvestri V, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res 1998;4:241-9.
18. Ohsaki Y, Tanno S, Fujita Y, Toyoshima E, Fujiuchi S, Nishigaki Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000;7: 603-7.
19. Meert AP, Martin B, Delmotte P, Berghmans T, Lafitte JJ, Mascaux C, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with metaanalysis. Eur Respir J 2002;20:975-81.
20. Reinmuth N, Brandt B, Kunze WP, Junker K, Thomas M, Achatzy R, et al. Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur Respir J 2000;16:991-6.
21. Raben D, Helfrich BA, Chan D, Johnson G, Bunn PA, Jr. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 2002;29:37-46.
22. Bishop PC, Myers T, Robey R, Fry DW, Liu ET, Blagosklonny MV, et al. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene 2002;21:119-27.
23. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6: 4885-92.
24. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20:2240-50.
25. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20:3815-25.
26. Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002;20: 4292-302.
27. Negoro S, Nakagawa K, Fukuoka M, Kudoh S, Tamura T, Yoshimura N, et al. Final results of a phase I intermittent dose-escalation trial of ZD1839 ('Iressa') in Japanese patients with various solid tumors. Proc Am Soc Clin Oncol 2001:20 (Abstract 1292).
28. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19:3267-79.
29. Rinehart JJ, Wilding G, Willson J, Krishnamurti S, Natale R, Mani S, et al. A phase 1 clinical trial and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002:21 (Abstract 41).
30. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14.
31. Miller VA, Johnson D, Heelan RT, Pizzo BA, Perez WJ, Bass A, et al. A Pilot Trial Demonstrates the Safety of ZD1839 ('Iressa'), an Oral Epidermal Growth Factro Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), in Combination with Carboplatin (C) and Paclitaxel (P) in Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC). In: Grunberg SM, ed. American Society of Clinical Oncology. San Francisco, California: American Society of Clinical Oncology; 2001.
32. Forero L, Patnaik A, Hammond LA, Tolcher A, Schwartz G, Hidalgo M, et al. Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin. In: Grunberg SM, ed. American Society of Clinical Oncology. Orlando, Florida: American Society of Clinical Oncology; 2002.
33. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J-Y, et al. A multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J Clin Oncol 2003:in press.
34. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP, et al. A phase II trial of ZD1839 ('Iressa') in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum-and docetaxel-based regimens (IDEAL2). In: Grunberg SM, ed. American Society of Clinical Oncology. Orlando, Florida: American Society of Clinical Oncology; 2002.
35. Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, et al. A phase II Trial of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinas Inhibitor OSI-774, Following Platinum-Based Chemotherapy, in Patients (pts) with Advanced, EGFR-Expressing, Non-Small Cell Lung Cancer (NSCLC). In: Grunberg SM, ed. American Society of Clinical Oncology. San Francisco, California: American Society of Clinical Oncology; 2001.
36. Johnson DH, Herbst R, Giaccone G, Schiller J, Natale RB, Miller V, et al. ZD1839 ("Iressa") in combination with paclitaxel & carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): Results from a phase III clinical trial (INTACT2). In: Kerr DJ, ed. European Society of Medical Oncology Congress. Nice, France: Oxford University Press; 2002:128.
37. Giaccone G, Johnson DH, Manegold C, Scagliotti GV, Rosell R, Wolf R, et al. A phase III clinical trial of ZD1839 ('Iressa') in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (INTACT 1). In: Kerr DJ, ed. European Society of Medical Oncology Congress. Nice, France: Oxford University Press; 2002:2.
38. Janne PA, Ostler PA, Lucca J, Fidias P, Skarin AT, Lynch TJ, et al. ZD1839 ('Iressa') shows antitumor activity in patients with recurrent non-small cell lung cancer treated on a compassionate use protocol. In: Grunberg SM, ed. American Society of Clinical Oncology. Orlando, Florida: American Society of Clinical Oncology; 2002.
39. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-9.
40. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26.
41. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ('Iressa') inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001;61:7184-8.
42. Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 2002;86:1449-56.
43. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 1993;53:2379-85.
44. Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997;3: 515-22.
45. Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res 2001;7:1850-5.
46. Volm M, Rittgen W, Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 1998;77:663-9.